Anhui Huaheng Biotechnology Co., Ltd. (SHA:688639)
China · Delayed Price · Currency is CNY 29.31
-0.27 (-0.91%)
Mar 30, 2026, 1:45 PM CST
SHA:688639 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 2,311 | 1,805 | 1,704 | 1,220 | 841.86 |
Other Revenue | 551.16 | 372.99 | 234.23 | 198.65 | 112.23 |
| 2,862 | 2,178 | 1,938 | 1,419 | 954.1 | |
Revenue Growth (YoY) | 31.40% | 12.37% | 36.63% | 48.69% | 95.81% |
Cost of Revenue | 2,270 | 1,639 | 1,156 | 870.26 | 646 |
Gross Profit | 591.62 | 538.54 | 782.37 | 548.39 | 308.1 |
Selling, General & Admin | 276.29 | 220.37 | 172.08 | 142.22 | 79.93 |
Research & Development | 151.2 | 124.05 | 108.82 | 78.61 | 52.84 |
Other Operating Expenses | 8.06 | -13.41 | 4.55 | 7.97 | 6.58 |
Operating Expenses | 434.9 | 329.79 | 285.77 | 231.29 | 139.03 |
Operating Income | 156.72 | 208.75 | 496.6 | 317.1 | 169.06 |
Interest Expense | -43.83 | -37.87 | -10.64 | -0.54 | -1.11 |
Interest & Investment Income | 6.79 | 5.25 | 5.91 | 10.64 | 7.5 |
Currency Exchange Gain (Loss) | -2.94 | 14.04 | 7.06 | 5.43 | -0.16 |
Other Non Operating Income (Expenses) | -4.73 | -3.3 | -2.66 | -0.59 | -0.39 |
EBT Excluding Unusual Items | 112.01 | 186.87 | 496.27 | 332.04 | 174.91 |
Gain (Loss) on Sale of Investments | -0.92 | - | -0.31 | -0.75 | 1.06 |
Gain (Loss) on Sale of Assets | 0.12 | -0.06 | -2.67 | -4.62 | -0.36 |
Asset Writedown | -1.86 | -0.31 | - | - | -5.61 |
Other Unusual Items | 16.2 | 14.9 | 12.98 | 16.32 | 20.78 |
Pretax Income | 125.56 | 201.41 | 506.27 | 342.98 | 190.79 |
Income Tax Expense | 1.7 | 16.85 | 59.67 | 23.64 | 22.55 |
Earnings From Continuing Operations | 123.86 | 184.56 | 446.6 | 319.34 | 168.24 |
Minority Interest in Earnings | 8.55 | 4.96 | 2.46 | 0.69 | - |
Net Income | 132.41 | 189.52 | 449.06 | 320.03 | 168.24 |
Net Income to Common | 132.41 | 189.52 | 449.06 | 320.03 | 168.24 |
Net Income Growth | -30.13% | -57.80% | 40.32% | 90.23% | 38.92% |
Shares Outstanding (Basic) | 250 | 231 | 229 | 227 | 208 |
Shares Outstanding (Diluted) | 250 | 231 | 229 | 227 | 208 |
Shares Change (YoY) | 8.10% | 0.88% | 0.72% | 9.33% | 22.57% |
EPS (Basic) | 0.53 | 0.82 | 1.96 | 1.41 | 0.81 |
EPS (Diluted) | 0.53 | 0.82 | 1.96 | 1.41 | 0.81 |
EPS Growth | -35.37% | -58.16% | 39.31% | 73.99% | 13.35% |
Free Cash Flow | -532.18 | -723.72 | -967.75 | -98.92 | -84.93 |
Free Cash Flow Per Share | -2.13 | -3.13 | -4.22 | -0.43 | -0.41 |
Dividend Per Share | 0.160 | 0.250 | 0.621 | 0.428 | 0.262 |
Dividend Growth | -36.00% | -59.72% | 44.99% | 63.33% | 63.51% |
Gross Margin | 20.67% | 24.73% | 40.36% | 38.66% | 32.29% |
Operating Margin | 5.48% | 9.59% | 25.62% | 22.35% | 17.72% |
Profit Margin | 4.63% | 8.70% | 23.17% | 22.56% | 17.63% |
Free Cash Flow Margin | -18.60% | -33.23% | -49.93% | -6.97% | -8.90% |
EBITDA | 371.52 | 347.41 | 595.44 | 376.25 | 216.56 |
EBITDA Margin | 12.98% | 15.95% | 30.72% | 26.52% | 22.70% |
D&A For EBITDA | 214.8 | 138.66 | 98.84 | 59.15 | 47.5 |
EBIT | 156.72 | 208.75 | 496.6 | 317.1 | 169.06 |
EBIT Margin | 5.48% | 9.59% | 25.62% | 22.35% | 17.72% |
Effective Tax Rate | 1.35% | 8.37% | 11.79% | 6.89% | 11.82% |
Revenue as Reported | 2,862 | 2,178 | 1,938 | 1,419 | 954.1 |
Advertising Expenses | 4.58 | 4.84 | 3.33 | 1.33 | 0.7 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.